从基于联盟的项目中提供监管影响

Nature Reviews Drug Discovery Pub Date : 2025-06-09 DOI:10.1038/d41573-025-00098-8

Martha A. Brumfield, Graham C. Higson, Cécile Ollivier, Nathalie Seigneuret

{"title":"从基于联盟的项目中提供监管影响","authors":"Martha A. Brumfield, Graham C. Higson, Cécile Ollivier, Nathalie Seigneuret","doi":"10.1038/d41573-025-00098-8","DOIUrl":null,"url":null,"abstract":"Multiple consortia have been established in the past two decades with the aim of tackling roadblocks in the development of medical products, often by developing new tools to support decision making by regulatory agencies. Here, we highlight lessons learned from these efforts that could help maximize the regulatory impact of consortium-based projects.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"90 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Delivering regulatory impact from consortium-based projects\",\"authors\":\"Martha A. Brumfield, Graham C. Higson, Cécile Ollivier, Nathalie Seigneuret\",\"doi\":\"10.1038/d41573-025-00098-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple consortia have been established in the past two decades with the aim of tackling roadblocks in the development of medical products, often by developing new tools to support decision making by regulatory agencies. Here, we highlight lessons learned from these efforts that could help maximize the regulatory impact of consortium-based projects.\",\"PeriodicalId\":18847,\"journal\":{\"name\":\"Nature Reviews Drug Discovery\",\"volume\":\"90 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/d41573-025-00098-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/d41573-025-00098-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在过去二十年中，已经建立了多个联盟，其目的是解决医疗产品开发中的障碍，通常是通过开发新工具来支持监管机构的决策。在这里，我们强调从这些努力中吸取的经验教训，这些经验教训可以帮助最大化基于联盟的项目的监管影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Delivering regulatory impact from consortium-based projects

Multiple consortia have been established in the past two decades with the aim of tackling roadblocks in the development of medical products, often by developing new tools to support decision making by regulatory agencies. Here, we highlight lessons learned from these efforts that could help maximize the regulatory impact of consortium-based projects.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Drug Discovery

自引率

0.00%

发文量